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Abstract
Ovarian cancer is one of the most lethal gynecological cancers; owning to its late detection and chemoresistance, under-
standing the pathogenesis of this malignant tumor is much critical. Previous studies have reported that ubiquitin-specific 
peptidase 39 (USP39) is generally overexpressed in a variety of cancers, including hepatocellular carcinoma, gastric cancer 
and so forth. Furthermore, USP39 is proved to be associated with the proliferation of malignant tumors. However, the func-
tion and mechanism of USP39 in ovarian cancer have not been elucidated. In the present study, we observed that USP39 
was frequently overexpressed in human ovarian cancer and was highly correlated with TNM stage. Suppression of USP39 
markedly inhibited the growth and migration of ovarian cancer cell lines HO-8910 and SKOV3 and induced cell cycle G2/M 
arrest. Moreover, knockdown of USP39 inhibited ovarian tumor growth in a xenograft model. In addition, our findings indi-
cated that cell cycle arrest induced by USP39 knockdown might be involved in p53/p21 signaling pathway. Furthermore, 
we found that the depletion of USP39 inhibited the migration of ovarian cancer cells via blocking epithelial–mesenchymal 
transition. Taken together, these results suggest that USP39 may play vital roles in the genesis and progression and may 
serve as a potential biomarker for diagnosis and therapeutic target of ovarian cancer.
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Introduction
As the second most common cancer among gynecologi-
cal malignancies, ovarian cancer remains one of the most 
frequent causes of death in female worldwide [1, 2]. Since 
malignant ovarian tumor normally grows in secluded places 
and the early symptoms of ovarian malignant tumors are not 
apparent, most of ovarian cancer patients are diagnosed at an 
advanced stage with the presentation of metastasis spreading 
beyond the ovary [3]. Owning to the lack of simple and 
practical diagnostic method, the treatment effects of ovar-
ian cancer are restricted severely. Therefore, it is necessary 
to study the molecular mechanisms of ovarian cancer and to 
seek a reliable diagnostic method. Besides, screening out a 
novel biomarker for prognostic prediction and looking for 
a molecular therapeutic target would be more promising in 
the treatment of advanced ovarian cancer.
Ubiquitin-specific peptidase 39 (USP39), which contains 
a central zinc finger and two ubiquitin C-terminal hydrolase 
(UCH) domains, belongs to deubiquitylation family ubiqui-
tin-specific proteases (USPs) [4]. Nevertheless, it is deprived 
of ubiquitin-specific peptidase activity due to the absence 
of the catalytic active amino acid residues [5, 6]. Besides, 
USP39 is well known as a 65-kDa serine/arginine (SR)-
related protein, for its N-terminal domain which is rich in 
arginine, serine and glutamic acids, similar to the RS domain 
of SR-related proteins, which is essential to recruit the tri-
snRNP to the pre-spliceosome to form a mature spliceo-
some [7]. Previous research showed that SR-related proteins 
(SRSF1, SRSF3, SRSF5, etc.) were often overexpressed in 
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ovarian cancer and closely related to proliferation, metastasis 
and prognosis of the malignancy [8–10]. Researchers have 
proved when SRSF1 was stimulated in ovarian cancer cells, 
it can be transported to the nucleus and affected the expres-
sion of p53 by regulating the splicing of p53 pre-mRNA, 
and the dysfunction of splicing of pre-mRNA thereby leads 
to the deletion mutation of p53 [9].
Recently, many effective researches have been imple-
mented aiming at the functions of USP39 in the genesis 
and development of malignancy. Researchers identified 
that USP39 may act as a new factor to maintain the spindle 
checkpoint and support successful cytokinesis, probably 
through regulating splicing of Aurora B and other mRNAs 
[5]. Wang et al. demonstrated that high level of USP39 was 
present in human breast tumor cells and regulated the cell 
survival and proliferation [11]. Pan et al. found that suppres-
sion of USP39 inhibited cell proliferation and colony for-
mation of human hepatocellular carcinoma cells along with 
cell cycle arrested at G2/M phase [12]. Other research dis-
covered that knockdown of USP39 significantly decreased 
medullary thyroid carcinoma cells’ proliferation and induced 
cell cycle arrested at G2/M phase, along with the down-
regulation of G2/M phase-associated proteins, such as cyc-
lin B1 and CDK1 [13]. In addition, USP39 was proved to 
be a target of SUMOylation specific protein (SENP), and 
overexpression of USP39 could enhance the proliferation 
of prostate cancer PC3 cells [14]. These findings suggested 
that USP39 may act as an essential oncogenic factor and play 
important roles in various cancers. However, the potential 
function and molecular mechanism of USP39 in ovarian 
cancer remain unclear.
The objection of this project was to explore the biological 
functions of USP39 in human ovarian cancer both in vivo 
and in vitro, to identify the molecular target of USP39 in 
HO-8910 and SKOV3 cell lines and to uncover the poten-
tial mechanism of USP39 which promotes ovarian cancer 
development, in an attempt to provide a novel perspective 
and theoretical basis for clinical early diagnosis and therapy 
of ovarian cancer.
Materials and methods
Reagents and antibodies
Roswell Park Memorial Institute-1640 (RPMI-1640), Dul-
becco’s modified eagle medium (DMEM), fetal bovine 
serum (FBS), trypsin/EDTA, and penicillin streptomycin 
were purchased from GIBCO (Grand Island, NY, USA); 
human TGF-β-Mammalian was purchased from Pepro-
Tech (Rocky Hill, USA). Pierce BCA Protein Assay Kit 
and RevertAid First Strand cDNA Synthesis kit were 
purchased from Thermo scientific (Rockford, USA); 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) 
and propidium iodide (PI) were purchased from Sigma-
Aldrich (St. Louis, MO, USA).
The following antibodies were used:
USP39 (ab131244) and CDK1 (ab32094) were purchased 
from Abcam; β-actin (A1978) was purchased from Sigma; 
slug (9585), β-catenin (8480) and cyclin B1(12231) were 
purchased from Cell signaling Technology; P53 (sc47698), 
P21 (sc-136020), P27(sc-71813), E-cadherin (sc-71009) and 
N-cadherin (sc-59987) were purchased from Santa Cruz.
Immunohistochemical analysis
Detect the expression level of USP39 protein by immunohis-
tochemistry staining on microarray tissue of human ovarian 
cancer with scoring procedure according to staining inten-
sity and the extent of straining, to count and analyze the 
distribution of USP39 in human ovarian cancer. Diamin-
obenzidine was used to visualize the immunohistochemical 
reaction, followed by counterstaining with hematoxylin. The 
immunohistochemistry (IHC) staining on tissue array was 
analyzed through standard light microscopy. Positive cells 
showed brown granules in the nucleus or cytoplasm. The 
positive cell percentage was determined by calculating the 
percentage of positive cells in total observed cells: 5%, 0; 
5–25%, 1; 25–50%, 2; 50–75%, 3; 75–100%, 4. The inten-
sity was decided by comparing the staining of tumor cells: 
no staining or ambiguous staining, 0; weakly staining, 1; 
medially staining, 2; strongly staining, 3. The staining was 
quantified according to the sum of the positive cells and the 
intensity to categorize: 0–1, negative (−); 2–4, positive (+); 
≥ 5, strongly positive (++).
Cell culture
The human ovarian cancer HO-8910 and SKOV3 cell lines 
(purchased from the Cell Bank of the Chinese Academy 
of Science, Shanghai, China) were maintained in RPMI-
1640 medium supplemented with 10% fetal bovine serum, 
100 U/ml penicillin and 0.1 mg/ml streptomycin at 37 °C 
in 5%  CO2. The human embryonic kidney cell line 293T 
(purchased from the American Type Culture Collection) was 
cultured in DMEM supplemented with 10% FBS, 100 U/ml 
penicillin and 0.1 mg/ml streptomycin at 37 °C in 5%  CO2.
Lentiviral vector production and infection
ShRNA sequences targeting USP39 (5′-GAA TAA CAT AAA 
GGC CAA T-3′) was inserted into lentivirus vector GV248 
(Hollybio. Inc. Shanghai, China). The shUSP39-expressing 
plasmid and Lenti-Easy Packaging Mix were co-transfected 
into 293T cells via the lipofectamine2000TM transfec-
tion reagent (Invitrogen) according to the manufacturer’s 
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instruction. Supernatants were collected 48 h after transfec-
tion, filtered through a 0.4-μm membrane and used to infect 
the cells. After 5 days of infection and selection with puro-
mycin, cells were observed under fluorescence microscopy. 
The USP39 expression levels in the selected stable clones 
were then verified by real-time PCR and Western blotting.
Quantitative real‑time PCR (qRT‑PCR)
Total RNA from HO-8910 and SKOV3 cells was extracted 
using TRIzol reagent (Takara); RNA was quantified using 
NanoDrop Spectrophotometer. As per manufacturer’s rec-
ommendations, 2 μg of RNA was used to generate comple-
mentary DNA using the  Hifair® II 1st Strand cDNA Synthe-
sis Kit (gDNA digester plus). Then, the measurements were 
taken using the SYBR Green system  (Hieff® qPCR SYBR 
Green Master Mix (No Rox)) in Light Cycler 96 Detection 
System (Roche). The primers used were as follows: usp39, 
5′-TTG GAA GAG GCG AGA TAA -3′and 5′-AGG AGC ATC 
AAT CAT CAT C-3′; β-actin, 5′-GTG GAC ATT CCG CAA 
AGA C-3′ and 5′- AAA GGG TGT AAC GCA ACT A -3′. Fold-
changes in mRNA levels were calculated. The β-actin was 
used as the reference gene; relative mRNA levels were deter-
mined with the  2−ΔΔCt. All experiments were repeated at 
least 3 times. Data shown are normalized to β-actin expres-
sion and represent the average of three repeated experiments.
Western blotting analysis
Western blotting was performed as previously described 
[15]. In short, samples were collected by lysing cells in 
RIPA lysis buffer. Each sample was size-fractionated using 
SDS–polyacrylamide gel electrophoresis (PAGE) and 
electro-transferred onto polyvinylidene difluoride transfer 
membranes (Dupont, Boston, MA, USA). After bolted with 
milk, the membranes were incubated with primary antibod-
ies overnight at 4 °C and then blotted with horseradish per-
oxidase conjugated secondary antibodies. The immunoblots 
were visualized using ECL (GE Healthcare, Bucks, UK).
Cell growth assay
Cells were seeded at a density of 2000 cells/well for five 
point-in-time (days 1, 2, 3, 4 and 5) in 96-well plates. Cell 
growth was assessed via MTT assay. We replace the medium 
mixed with MTT after 4 h by 150 μl DMSO and vibrate the 
96-well plates for 10 min. The absorbance at 570 nm was 
measured to evaluate cell viability.
Colony formation assay
Cells were seeded evenly in 12-well plates at a concentra-
tion of 500 cells/well and cultured at 37 °C for 12 days. The 
culture medium was changed every 3 days. The cells were 
washed with phosphate-buffered saline (PBS) twice and 
fixed in 4% paraformaldehyde for 30 min and stained with 
crystal violet for 20 min and then washed with PBS three 
times. The plates were photographed with a digital camera.
Cell cycling distribution assay
The cells were harvested by centrifugation at 1200 rpm for 
5 min, resuspended with ice-cold PBS twice, fixed with 
cold 70% ethanol at 4 °C overnight and then centrifuged at 
1500 rpm for 5 min to discard ethanol and resuspended with 
ice-cold PBS twice. The cell pellets were suspended in pro-
pidium iodide staining solution (20 mg/ml propidium iodide 
and 0.2 mg/ml RNase in PBS) and incubated for 30 min at 
37 °C. Cell cycle distribution was finally analyzed by flow 
cytometry.
Wound‑healing assay
Cells were seeded onto 12-well plates, and when they 
reached over 90% confluence, a scratch was made across the 
cell monolayer with the tip. Cells were gently washed with 
PBS for three times and maintained in the fresh medium 
with FBS. Cells were incubated for 24 h and photographed 
using an inverted tissue culture microscope. The migration 
potential between two different cells was compared by rela-
tive gap distance.
Xenograft assays in nude mice
For xenograft experiments, stable knockdown HO-8910 
cells and its control cell line (2 × 106) were implanted 
separately and subcutaneously into the right foreleg of the 
female Balb/c nude mice (n ≥ 3). The mice were moni-
tored every 2 days to measure the tumors volume. After 
30 days, the mice were killed and tumor weight was meas-
ured. Nude mice were used at 4–6 weeks of age. Tumor 
volume = 0.5 * a2 * b (a, width; b, length).
Statistical analysis
The results of the experimental studies are expressed as the 
mean ± S.D. for at least three separate determinations for 
each group. The differences between the groups were exam-
ined for statistical significance using the Student’s t test. 
p < 0.05 was considered to indicate statistical significance.
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Results
USP39 is frequently overexpressed and highly 
related to TNM stage in human ovarian cancer
To evaluate USP39 protein level and distribution in human 
ovarian cancer tissues, we tested ovarian cancer tissue 
microarray by using immunohistochemistry (IHC) stain-
ing. The microarray contained 156 ovarian carcinoma 
patient samples, including 8 normal tissues, 26 benign 
tissues and 122 malignant tumor tissues. Representative 
immunohistochemical results and quantitative analysis of 
ovarian carcinoma tissues are shown in Fig. 1a, b. USP39 
was strongly expressed in the ovarian cancer tissues, and 
positive staining of USP39 was detected mainly in the 
nucleus and partly distributed in the cytoplasm (Fig. 1a, 
b). In addition, we also analyzed the expression of USP39 
mRNA in human ovarian carcinoma using Oncomine data-
base (https ://www.oncom ine.org) and GEPIA database 
(http://gepia .cance r-pku.cn/detai l.php). These results also 
demonstrated that gene USP39 expression was increased 
in ovarian carcinoma samples (Fig. 1c–e). Then, we ana-
lyzed whether USP39 expression was associated with clin-
ical pathological characteristics of ovarian carcinoma. As 
shown in Table 1, USP39 was significantly increased in 
malignant tumor (94.26%) compared with normal ovarian 
tissues (37.5%) and benign ovarian tumor tissues (76.92%) 
(p < 0.05). Besides, the expression of USP39 was different 
between I and II/III TNM stage. At the stage I, 11.11% 
(6/55) cases showed negative expression, 31.48% (17/55) 
cases showed weak expression, and 59.26% (32/55) cases 
displayed strong expression; at the stage II/III, USP39 
negative expression, weak expression and strong posi-
tive expression occupied 1.49% (1/67), 23.88% (16/67) 
and 76.63% (50/67), respectively. In addition, no evidence 
showed USP39 expression which was related to tumor his-
tological type and age (p > 0.05). The data above demon-
strated that USP39 was overexpressed in ovarian cancer 
tissues and was related to the TNM stage significantly 
(p < 0.05). 
Efficient knockdown of USP39 
by lentivirus‑mediated shRNA in HO‑8910 
and SKOV3 cells
To further determine the role of USP39 in ovarian cancer, 
we examined the expression level of USP39 in seven ovar-
ian cancer cell lines (TOV-21G, OV2008, HEY, SKOV3, 
HO-8910, C13 and A2780S) by Western blotting (WB) 
and found that HO-8910 and SKOV3 possessed the higher 
Fig. 1  Expression of USP39 is associated with ovarian carcinoma. 
A IHC staining of USP39 expression in normal and ovarian cancer 
tissues. Representative images of USP39 expression in normal ovar-
ian tissues (a, 100 ×; g, 200 ×), struma ovarian tissues (b, 100 ×; h, 
200 ×), thecoma tissues (c, 100 ×; i, 200 ×), serous adenocarcinoma 
tissues (d, 100 ×; j, 200 ×), mucinous adenocarcinoma tissues (e, 
100 ×; k, 200 ×) and endometrioid adenocarcinoma tissues (f, 100 ×; 
l, 200 ×). USP39 mostly located in the nucleus. B Quantitative analy-
sis of IHC assay showed that USP39 protein was strongly expressed 
in the ovarian cancer tissues compared with normal ovarian tissues. 
C–E Gene expression data from Oncomine database and GEPIA 
database showed that USP39 mRNA level was overexpressed in 
human ovarian carcinoma (**p < 0.01; ***p < 0.001; ****p < 0.0001)
◂
Table 1  An ovarian tissue 
microarray was stained with 
anti-human USP39 antibody 
(1:150)
Cases USP39
− + ++ X2 p
Tissue type 35.98 < 0.05
 Normal ovarian tissues 8 5 3 0
 Benign tumor 26 6 14 6
 Malignant tumor histological 122 7 33 82
Tumor histological type 5.88 > 0.05
 Serous adenocarcinoma 62 3 17 42
 Mucinous adenocarcinoma 20 2 7 11
 Endometrioid adenocarcinoma 32 2 9 21
 Granulosa cell tumor 4 0 0 4
 Undifferentiated carcinoma 4 0 0 4
TNM stage 6.24 < 0.05
 I 55 6 17 32
 II/III 67 1 16 50
Age 2.61 > 0.05
 ≥ 50 76 4 17 55
 < 50 46 3 16 27
 Medical Oncology (2019) 36:95
1 3
95 Page 6 of 13
expression level of USP39 (Fig. 2a). Therefore, we sup-
pressed USP39 expression in HO-8910 and SKOV3 by 
USP39 shRNA lentivirus. The infection efficiency of lentivi-
rus was about 90% as represented by the percentage of GFP 
expression cells, which were subjected to functional analysis 
(Fig. 2b, c). Real-time PCR and WB indicated that USP39 
was reduced about 80% in both the mRNA and protein levels 
(Fig. 2d–g). These results indicated that USP39 expression 
was specific and efficient knockdown by lentivirus-mediated 
shRNA in HO-8910 and SKOV3 cells.
Knockdown of USP39 inhibits ovarian carcinoma 
growth in vitro and in vivo
To verify the role of USP39 on cell growth in vitro, MTT 
assay and colony formation were performed in HO-8910 
and SKOV3 cells. The number of USP39 shRNA-transfected 
cells was reduced significantly compared with negative con-
trols (Fig. 3a, b). Likewise, we demonstrated that USP39 
knockdown resulted in significantly reduction in the colony 
formation compared with the control group (Fig. 3c, d). 
Fig. 2  Efficiency of suppression USP39 in HO-8910 and SKOV3 
cells. a The protein level of USP39 in ovarian cancer cell lines: TOV-
21G, OV2008, HEY, SKOV3, HO-8910, C13 and A2780S. USP39 
expression in HO-8910 and SKOV3 cells was extremely higher 
than in other five cell lines. b, c Lentiviral infection in HO-8910 and 
SKOV3 cells. Representative GFP expression in control, shCon and 
shUSP39 in HO-8910 and SKOV3 cells. Upper panel, bright field; 
lower panel, fluorescence field (200 ×). d–g Real-time PCR and 
Western blot revealed the expression of USP39 mRNA and protein 
was efficiently inhibited in HO-8910 and SKOV3 cells (**p < 0.01; 
***p < 0.001; ****p < 0.0001)
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These results indicated that knockdown of USP39 markedly 
inhibited the proliferative ability of ovarian cancer in vitro.
To further investigate whether USP39 suppression inhib-
ited ovarian tumorigenesis in vivo, we constructed HO-8910 
xenograft model. We injected USP39 stable knockdown 
HO-8910 cell line (shUSP39) and the control cell line 
(shCon) into BALB/c nude mice separately, and monitored 
local tumor formation for 30 days. Results showed that the 
volume and weight of tumors in USP39 knockdown group 
were significantly lower than in control group (Fig. 3e–g). 
Taken together, these results indicated that USP39 suppres-
sion inhibited ovarian carcinoma growth both in vitro and 
in vivo, and USP39 is critical for ovarian cancer cell prolif-
eration and tumorigenesis.
Fig. 3  Effect of USP39 knockdown on proliferation of ovarian cancer 
cells in  vitro and vivo. a, b USP39-shRNA targeted cells and con-
trol cells were observed by Cellomics for 5 days. The growth curve 
of HO-8910 and SKOV3 cells infection of shUSP39. c, d Images of 
crystal violet-stained colonies of HO-8910 and SKOV3 cells grow-
ing in 6-well plates after 14 days. Corresponding statistics analysis of 
crystal violet-stained colonies of two groups. e USP39 suppression in 
HO-8910 cells decreased xenografted tumor growth in nude mice. f, 
g Tumor weight and size in USP39 knockdown group were signifi-
cantly reduced compared with the negative control group (*p < 0.05; 
**p < 0.01; ***p < 0.001)
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Knockdown of USP39 induces G2/M arrest in ovarian 
cancer cells
To further explore the underlying mechanism of the inhibi-
tion of proliferation by reducing the expression of USP39, 
we employed flow cytometry to detect DNA content in PI-
staining cells to analyze whether it was induced by cell cycle 
abnormality. As depicted in Fig. 4a, b, compared with the 
control group, knockdown of USP39 induced G2/M arrest in 
HO-8910 and SKOV3 cells. Further investigation was per-
formed to locate the molecular mechanisms on how USP39 
regulates cell cycle arrest in G2/M phase in human ovarian 
cancer cells. The Western blot analysis showed that knock-
down of USP39 down-related the expression of CDK1 and 
cyclin B1 (Fig. 6a, b). These results implied that prolifera-
tion inhibition might be associated with cell cycle arrest and 
strongly supported that USP39 plays an important role in the 
malignant growth of ovarian carcinoma.
Silencing USP39 blocks the migration of HO‑8910 
and SKOV3 cells
To investigate whether USP39 affects the migration abil-
ity of ovarian cancer cells, we performed a wound-healing 
assay. The results showed that the velocity of wound repair-
ing in the shCon group was faster than in the shUSP39 group 
at 12 h and 24 h (Fig. 5a, b). These results indicated that 
knockdown of USP39 could block the migration of HO-8910 
cells in vitro.
Knockdown of USP39 activates P53 signaling 
pathway and blocks EMT transition
To investigate the molecular mechanism of USP39 on the 
proliferation and migration of ovarian cancer, we detected 
cell cycle and EMT-related regulators by Western blotting 
assay. We found that USP39 suppression could up-regulate 
the protein level of p53 and p21 (a downstream target of 
p53), but had no significant effect on p27 (Fig. 6c, d), sug-
gesting that G2/M arrest induced by USP39 silencing might 
Fig. 4  USP39 silencing induced G2/M cell cycle arrest. Flow cyto-
metric assay was employed to analyze the cell cycle distribution. a, 
b Knockdown of USP39 in ovarian cancer cells changed cell cycle 
distribution. The percentage of cells in the G2/M phase was evi-
dently increased, compared with the control group (**p < 0.01; 
***p < 0.001)
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be associated with p53/p21 signaling pathway. In addi-
tion, we tested EMT-related proteins, including β-catenin, 
N-cadherin, E-cadherin and slug (a downstream target gene 
of Wnt/β-catenin). As shown in Fig. 6e, f, we found that 
β-catenin, N-cadherin and slug were decreased and E-cad-
herin was increased in the wake of USP39 knockdown. Fur-
thermore, cell morphological analysis showed that EMT 
transition was blocked (Fig. 6g). These findings implied that 
silencing of USP39 inhibited migration of ovarian cancer 
cells via blocking EMT transition.
Discussion
So far, researchers have discovered and named nearly 100 
deubiquitinating enzymes, which are divided into five fami-
lies; among them, ubiquitin-specific protease (USP) family 
is the one of the biggest [4]. USPs are involved in many cel-
lular processes, including proliferation of tumor [11], cell 
cycle [16], cell apoptosis [17] and tumor metastasis [18]. 
Many reports have indicated that some members of USPs 
are highly connected with cancers, such as USP2a, USP4, 
USP5, USP7, USP10, USP13 and USP39 [19–24]. Previ-
ous studies have reported that USP39 plays important roles 
in mRNA splicing [6], mitosis processing, and act as an 
oncogene in several cancers [11, 24]. But up to now, the 
underlying function and potential mechanism of USP39 in 
ovarian cancer are still elusive.
In the present study, we observed that USP39 protein was 
significantly increased in ovarian cancer tissues compared 
with normal tissues, and the high level of USP39 was related 
to TNM stage, which is likely to be used as a clinical diag-
nostic basis of high grade of malignancy and poor progno-
sis in ovarian cancer. Subsequently, we tested the expres-
sion level of USP39 in seven ovarian cancer cell lines and 
chose HO-8910 and SKOV3 to explore the role of USP39. 
Lentivirus-delivered short hairpin RNA (shRNA) targeting 
USP39 was employed to stably down-regulate its endog-
enous expression. Knockdown of USP39 markedly inhibited 
cell proliferation and the ability of colony formation. Flow 
cytometry analysis showed that USP39 knockdown induced 
G2/M arrest, which could contribute to the inhibition of cell 
Fig. 5  Knockdown of USP39 affected migration of ovarian cancer cells. a, b Representative images of wound healing of HO-8910 and SKOV3 
cells infected with shUSP39 and shCon. Silencing of USP39 inhibited the migration of ovarian cancer cells (*p < 0.05; **p < 0.01)
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proliferation. Additionally, the suppression of USP39 inhib-
ited the cell migration, which was so distinguished in previ-
ous investigates as well. Furthermore, we found that p53/
p21 pathway and EMT were involved with the cell cycle 
processing and cell migration, respectively.
p53 is well known as a tumor suppressor, which regu-
lates the G0/G1 and G2/M cell cycle checkpoints [25], 
while p27 controls the G1/S cell cycle checkpoint [26]. p21 
is a downstream gene of p53, functioning as a link between 
p53 and cell cycle [27]. In this study, we observed that the 
human ovarian cancer cells, expressing a wild-type form 
of p53, were arrested at the G2/M phase of the cell cycle 
after shUSP39 interference. Then, we found a significant 
increase in p21, but not in p27, indicating that knockdown 
of USP39 in ovarian cancer cells resulted in accumulation 
of p53 and p21, and induced G2/M but not G1/S cell cycle 
arrest, suggesting that a p53 independent pathway may be 
involved in inducing the USP39-related changes. It is known 
that p53 regulates the G2/M checkpoint via modulating the 
cycle-dependent kinase Cdc2, which is essential for the entry 
of cells into mitosis [28]. p21 is the transcriptional targets 
of p53; it can inhibit Cdc2 by anchoring Cdc2 in the cyto-
plasm where it cannot induce mitosis [29]. A recent research 
showed that knockdown of USP39 induced the down-reg-
ulation of Cdc2 and cyclin B1 in medullary thyroid carci-
noma, resulting in G2/M phase arrest [13]. Taken together, 
we speculate that USP39 regulated G2/M phase mediated 
by p53/p21/Cdc2/cyclin B1 pathway (described in Fig. 7).
It is well known that ovarian cancer cells are prone to 
metastasis; in this process, epithelial-to-mesenchymal 
transition (EMT) is a necessary step during detachment 
of tumor cells from the primary tumor site and attachment 
to metastatic sites [30]. To ascertain the role of USP39 
in migration, we observed that knockdown of USP39 in 
HO-8910 and SKOV3 cells inhibited the migration of 
ovarian cancer cells, as assessed by scratch-wound assay. 
Then, we further checked the EMT markers. A switch from 
E-cadherin to N-cadherin is a key feature of EMT in ovar-
ian cancer [31]. E-cadherin is a transmembrane glycopro-
tein of the type-I cadherin superfamily. Its cytoplasmic 
part is linked to the actin cytoskeleton via the catenins 
[30]. Wnt/β-catenin signaling has a major impact on EMT 
during cancer progression [32, 33]. Wnt signal activation 
forced a rapid increase in the level of cytosolic β-catenin 
and enabled β-catenin to translocate and accumulate in the 
nucleus where it binds to TCF/LEF transcription factors, 
and induced the downstream target gene slug transcription 
[34, 35]. Reduction in E-cadherin levels often released 
β-catenin from adherens junction, resulting in nuclear 
β-catenin accumulation, and the consequent transactiva-
tion of a panel of target genes [32, 36]. In our experi-
ment, knockdown of USP39 significantly decreased the 
N-cadherin and increased the E-cadherin expression at the 
protein levels, and reduced the protein levels of β-catenin 
and slug. Slug is a transcription inhibitor of E-cadherin; 
the down-regulation of slug further promotes the expres-
sion of E-cadherin and finally leads to EMT inhibition. 
Therefore, we proposed that USP39 might promote EMT 
by activating Wnt/β-catenin/TCF/slug/E-cadherin pathway 
(described in Fig. 7).
Our study provided substantial evidences in supporting 
that USP39 is overexpressed in most of ovarian cancer cells, 
Fig. 6  Regulated mechanism of USP39 knockdown in ovarian can-
cer cells. a, b The total protein was extracted, and the expression of 
cell cycle-related proteins was analyzed by Western blot assay. c, d 
Knockdown of USP39 activated the P53 signaling pathway. e–g 
USP39 suppression blocked the EMT of ovarian cancer cells. Data 
are reported as mean ± SD of three replicate experiments (*p < 0.05; 
***p < 0.001)
◂
Fig. 7  USP39 promotes pro-
gression of ovarian cancer cells 
via blocking P53/P21 pathway 
and activating β-catenin/LEF/
TCF/slug pathway
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and suppression of USP39 reduces proliferation and migra-
tion activity. Moreover, we revealed the potential molecular 
mechanism of USP39 in ovarian cancer cells, which might 
be involved with p53/p21 pathway and EMT transition. In 
conclusion, we proposed that USP39 acts as an oncogenic 
factor, and it has great potential to be a clinical biomarker 
in diagnosing ovarian cancer, or even be a gene target in 
treating ovarian cancer patients.
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